Johnson & Johnson (NYSE:JNJ) Stock Holdings Lifted by Chartwell Investment Partners LLC

Chartwell Investment Partners LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 2.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 181,051 shares of the company’s stock after buying an additional 3,601 shares during the quarter. Johnson & Johnson makes up 1.0% of Chartwell Investment Partners LLC’s investment portfolio, making the stock its 10th largest holding. Chartwell Investment Partners LLC’s holdings in Johnson & Johnson were worth $29,341,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Meridian Financial Partners LLC purchased a new stake in Johnson & Johnson during the second quarter worth about $1,626,000. Lmcg Investments LLC increased its stake in shares of Johnson & Johnson by 32.7% during the 3rd quarter. Lmcg Investments LLC now owns 87,162 shares of the company’s stock worth $14,125,000 after purchasing an additional 21,471 shares during the last quarter. NTV Asset Management LLC raised its holdings in shares of Johnson & Johnson by 1.6% in the 1st quarter. NTV Asset Management LLC now owns 36,000 shares of the company’s stock worth $5,695,000 after purchasing an additional 565 shares during the period. Cooper Haims Advisors LLC grew its holdings in Johnson & Johnson by 6.4% during the first quarter. Cooper Haims Advisors LLC now owns 3,358 shares of the company’s stock valued at $531,000 after purchasing an additional 201 shares during the period. Finally, Trajan Wealth LLC increased its position in Johnson & Johnson by 11.3% in the third quarter. Trajan Wealth LLC now owns 32,992 shares of the company’s stock worth $5,347,000 after buying an additional 3,341 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $155.05 on Tuesday. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The stock has a market cap of $373.30 billion, a P/E ratio of 22.44, a PEG ratio of 2.76 and a beta of 0.53. The business’s 50-day moving average price is $162.61 and its two-hundred day moving average price is $155.91.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. Johnson & Johnson’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.66 earnings per share. As a group, equities analysts predict that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a yield of 3.20%. Johnson & Johnson’s payout ratio is 71.78%.

Analyst Ratings Changes

A number of research analysts have recently commented on JNJ shares. TD Securities dropped their price target on Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. TD Cowen cut their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. Royal Bank of Canada boosted their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Finally, Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Seven analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $175.00.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.